Cite
Durez P, Pavelka K, Lazaro MA, et al. Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial. Clin Rheumatol. 2018;37(7):2017-2018doi: 10.1007/s10067-018-4131-1.
Durez, P., Pavelka, K., Lazaro, M. A., Garcia-Kutzbach, A., Moots, R. J., Amital, H., Govoni, M., & Vastesaeger, N. (2018). Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial. Clinical rheumatology, 37(7), 2017-2018. https://doi.org/10.1007/s10067-018-4131-1
Durez, Patrick, et al. "Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial." Clinical rheumatology vol. 37,7 (2018): 2017-2018. doi: https://doi.org/10.1007/s10067-018-4131-1
Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H, Govoni M, Vastesaeger N. Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial. Clin Rheumatol. 2018 Jul;37(7):2017-2018. doi: 10.1007/s10067-018-4131-1. PMID: 29752584.
Copy
Download .nbib